Every laboratory running in-vitro work keeps two lists at once. One is the long list of materials that exist and can be sourced; the other is the short list that a specific study has actually justified. The first belongs to the supplier and shifts with stock, packaging and documentation. The second belongs to the scientist, the risk assessment and the assay design. Problems begin when a catalogue filter is quietly promoted into a quarterly reagent formulary — a habit borrowed from clinical settings, where an approved list carries a governance weight that a supplier’s category page was never built to bear.

For researchers and materials managers screening research-use-only (RUO) supplies, the more useful question is not “is this on the list?” but “which entries survive our criteria for this experiment, and on what evidence?” Keeping those two questions separate is what stops a browsing exercise from hardening into a pseudo-approval system.

A Catalogue Is a Screening Surface, Not an Approved List

A formulary is an instrument of governance: a curated set of items, revisited on a cycle, backed by an approval trail and carrying a presumption of continuing suitability until the next review. A research catalogue is none of those things. It describes what exists in a range at a given point, how each item is presented, what documentation travels with it and how it is fulfilled. It makes no presumption about whether an item suits your assay, your diluent system or your detection method.

That distinction matters because listings move. Restocks occur, descriptions are refined, packing materials vary, and analytical documentation is tied to a batch rather than to the page itself. A shortlist snapshotted in one quarter and treated as settled can be quietly stale a few months later while still looking authoritative on a shared drive. Filtering, by contrast, is a repeatable act: it narrows a long range against explicit criteria and yields a shortlist with reasons attached to each inclusion and, just as importantly, each exclusion.

Exclusion reasons are the part most teams skip. A note reading not this time — incompatible with the buffer system, revisit if the assay changes saves the next reviewer from reopening the same question from scratch, and prevents a filter from hardening into folklore. Ownership helps too. The scientist owns the question: what the in-vitro model requires. The materials manager owns the evidence: whether the listing, the batch CoA and the handling requirements are documented and consistent. Neither role should be quietly certifying permanent suitability.

On the Research Sciences all-products category, the published description frames the range as research peptides, laboratory accessories and preparation tools supporting in-vitro laboratory studies. That is a statement about range and purpose, not an endorsement for any protocol. All items are research-use-only — not for human or veterinary use — and the purchaser remains responsible for lawful use, safe handling and disposal, including compliance with COSHH and local laboratory standards. The vocabulary worth adopting is screening register, evaluation shortlist and batch approval; not preferred list, standing order or annual formulary.

Screening Criteria That Match the Assay, Not the Shopping Habit

Criteria should be written before browsing begins, otherwise the catalogue writes them for you. Four categories cover most in-vitro requirements: presentation, documentation, handling and excipient content. Anything that cannot be evidenced against those four stays off the shortlist, however familiar the item feels.

Presentation, excipients and handling

The range mixes peptides supplied as lyophilised powders with accessory items such as a Storage Container and Bacteriostatic Water 10ml, which also appears under the 10ml Mixing Water wording; reconstitution solutions are supplied separately from the peptides themselves. Visible listings include BPC-157 10mg, TB-500 5mg, GHK-Cu 50mg, Ipamorelin 5mg, CJC-1295 (No DAC) 5mg, Tesamorelin 5mg and MT-1 10mg, but each product page should be read as a specification sheet for that item alone rather than a template applied across the range.

Two details deserve a place in any screening record. First, the FAQs state that all peptides contain trace amounts of mannitol — relevant when an assay is sensitive to sugar alcohols or when blank controls must mirror excipient content. Second, handling: lyophilised material is stored at –20°C or below, sealed with desiccant and protected from moisture, heat and light, with repeated freeze–thaw cycles avoided; after reconstitution in a laboratory workflow it is held at 2–8°C for short-term use. Vials should reach room temperature before opening, work should take place in a clean environment, and only the amount required for the experiment removed. The shop does not supply blended peptides and recommends buying individually and combining only within a controlled experimental design — which suits screening, since a blend conceals attribution.

Reviewing the range against those criteria

Once criteria exist, the range review is short. Open the all-products view, sort candidates against the criteria, and open each survivor’s own page. Researchers who Buy peptides uk from that listing are selecting a batch and a document trail as well as a vial, so the product page and its CoA belong together in the record. The free reconstitution calculator described on product pages and in the FAQs is for laboratory research use only and must not be used for human or veterinary dosing.

Documentation and Review Rhythm Without a Formulary Cycle

The trigger for re-evaluation should be documentary rather than calendrical. A new batch, a fresh CoA, a changed assay or an altered risk assessment each justify reopening a decision; a date on a wall planner does not. A periodic sweep still has administrative value, but it should confirm that documents match batches, not re-bless a list.

What the batch document should tell you

The FAQs state that a CoA accompanies every product, covering purity and identity by HPLC. The About page describes full-spectrum testing — purity, identity, heavy metals and endotoxin evaluation — with CoAs linked to supported products, and the homepage lists “CoAs Janoshik Analytical Reports”. The homepage’s “≥99% Verified Purity” line is the shop’s own published wording and should be treated as a prompt to confirm the exact figure on the batch CoA rather than a substitute for it; the same applies to any published order, dispatch or support figure, which should be reconfirmed against current site wording and the accompanying batch documentation.

Three caveats are worth carrying into any register. Restocked products may share an Internal Test Reference with earlier stock: an ITR links to associated sample testing reports, but does not confirm that separate deliveries came from the same production lot or underwent separate independent testing. Vial cap colours and other packaging may vary, and cap colour is not an indicator of identity, analytical quality or manufacturing origin. Vial labels combine SKU and expiry, for example BPC10-03/27; quote that reference when querying documentation.

Naming, payment and fulfilment notes for the record

The FAQs describe Research Sciences as the parent company of Imperial Peptides UK, which continues to operate as a brand, so older documents circulating under Imperial Sciences UK or Imperial Peptides UK wording should be matched on label reference rather than logo. Payment is described as Pay-By-Bank / Open Banking, with card payments not accepted; orders are dispatched the next working day by Royal Mail Tracked 24, an estimate rather than a guarantee, and returns are not accepted once dispatched except for damage, incorrect supply or quality issues under the published policy. None of this converts a listing into an approval — and none of it changes the status of the materials, which remain research-use-only and not for human or veterinary use throughout.